The U.S. Senate passed a $550 billion bipartisan infrastructure bill aimed at shoring up the nation's roads and bridges, as well as protecting vulnerable communities from wildfires and expanding broadband internet access. The bill will now move to the House of Representatives, where Democratic lawmakers are planning to pair it with a $3.5 trillion bill that can be passed
Photo by Anna Moneymaker-Pool/Getty Images
A rebate rule the Biden Administration had already delayed until March 22 has been pushed out further to January 1, 2023.
The rule, scheduled under the Trump Administration to take effect on January 1, 2022, is being delayed by court order issued January 30, in a lawsuit by the Pharmaceutical Care Management Association against the Department of Health and Human Services.
PCMA is challenging the rule that would replace safe harbor protections for drug rebates in Medicare Part D with discounts for consumers at the pharmacy counter.
The case is being held in abeyance pending the duration of HHS s review of the November 20, 2020 rule. The parties have been ordered to submit a joint status report identifying whether and how this case should proceed by not later than April 1.
Rebate Rule Implementation Date Would Bring Chaos to Medicare Part D Program January 26, 2021 (Washington, D.C.) The Pharmaceutical Care Management Association (PCMA) has filed a motion for summary judgment to vacate the effective date of the Trump Administration’s rebate rule. The motion for summary judgment, filed in the U.S. District Court for the District of Columbia, seeks to vacate the January 1, 2022 effective date for the rebate rule with respect to Part D. The motion is vitally important to ensuring the stability of the Medicare Part D program as the Biden Administration reviews the Trump Administration’s “midnight regulations” and PCMA proceeds with litigation to revoke the rule in its entirety.
To embed, copy and paste the code into your website or blog:
In part two, Wiley Health Care Practice partners Dot Powell-Woodson and Rachel Alexander continue their discussion of the Most-Favored Nations (MFN) Rule and the Rebate Rule and look at the potential impacts of these Final Rules on managed care companies.
Embed